Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
41,859,564
-
Share change
-
+1,942,109
-
Total reported value
-
$3,175,408,396
-
Put/Call ratio
-
100%
-
Price per share
-
$75.78
-
Number of holders
-
417
-
Value change
-
+$68,797,438
-
Number of buys
-
192
-
Number of sells
-
214
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2021
As of 31 Dec 2021,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
417 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
41,859,564 shares.
The largest 10 holders included
ARK Investment Management LLC, Nikko Asset Management Americas, Inc., Capital International Investors, NEA Management Company, LLC, LOOMIS SAYLES & CO L P, BlackRock Inc., CREDIT SUISSE AG/, PRICE T ROWE ASSOCIATES INC /MD/, EcoR1 Capital, LLC, and Bellevue Group AG.
This page lists
419
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.